The Experts below are selected from a list of 21 Experts worldwide ranked by ideXlab platform

Tohru Mizushima - One of the best experts on this subject based on the ideXlab platform.

  • Aldioxa improves delayed gastric emptying and impaired gastric compliance, pathophysiologic mechanisms of functional dyspepsia
    Scientific Reports, 2015
    Co-Authors: Teita Asano, Shuji Aida, Shintaro Suemasu, Kayoko Tahara, Ken-ichiro Tanaka, Tohru Mizushima
    Abstract:

    Delayed gastric emptying and impaired gastric accommodation (decreased gastric compliance) play important roles in functional dyspepsia (FD). Here we screen for a clinically used drug with an ability to improve delayed gastric emptying in rats. Oral administration of Aldioxa (dihydroxyaluminum allantoinate) partially improved clonidine- or restraint stress-induced delayed gastric emptying. Administration of allantoin, but not aluminium hydroxide, restored the gastric emptying. Both Aldioxa and allantoin inhibited clonidine binding to the α-2 adrenergic receptor, suggesting that antagonistic activity of the allantoin moiety of Aldioxa on this receptor is involved in the restoration of gastric emptying activity. Aldioxa or aluminium hydroxide but not allantoin restored gastric compliance with restraint stress, suggesting that aluminium hydroxide moiety is involved in this restoration. We propose that Aldioxa is a candidate drug for FD, because its safety in humans has already been confirmed and its ameliorating effect on both of delayed gastric emptying and impaired gastric compliance are confirmed here.

Sun Guo-hui - One of the best experts on this subject based on the ideXlab platform.

  • Clinical efficacy and safety of Aldioxa granules in the treatment of gastritis and peptic ulcer
    Chinese New Drugs Journal, 2004
    Co-Authors: Sun Guo-hui
    Abstract:

    Objective:To observe the clinical efficacy and safety of Aldioxa granules in the treat-ment of peptic ulcer and acute or chronic gastritis. Methods: Multicenter, randomized, single-blinded, controlled clinical trials were performed on 132 patients,including 32 cases of gastric ulcer (16 cases of treatment and 16 cases as control) ,32 cases of duodenal ulcer (16 cases of treatment and 16 cases as control) ,68 cases of gastritis (34 cases of treatment and 34 cases as control). Patients of treatment group were given Aldioxa granules 0.2,tid;while patients of control group were given teprenone 50mg, tid. Treatment course was 4 weeks for both groups. Results:Remission of pain after 4 weeks for treatment group vs control group: 100 % vs 96.55 % for peptic ulcer, 79.31 % vs 78.46 % for gastritis, with no statistical significance. Remission of acid reflux,heart burn,nausea,abdominal distension and regur-gitation gastritis and peptic ulcer in the treatment group were similar to those in control group(P 0.05). Endoscopic examination: rate of healing of peptic ulcer for treatment vs control group was 87.49% vs 48.28% ,and for gastritis was 85.29% vs 55.17% ,with significant statistical difference. Elevation of prostaglandin level in gastric mucosa of (1794.23±3 474.53) ng·g-1 of tissue in treatment group, with significant statistical difference comparing to the control group [ - (925. 61±7 099.59)ng·g-1]. Conclusion: Aldioxa granules is a good therapeutic drug for peptic ulcer,suitable for treatment of peptic ulcer and acute or chronic gastritis.

Luo Zhong-hua - One of the best experts on this subject based on the ideXlab platform.

  • Efficacy of Aldioxa tablets in combination with rabeprazole on peptic ulcer
    Chinese Journal of Hospital Pharmacy, 2010
    Co-Authors: Luo Zhong-hua
    Abstract:

    OBJECTIVE To observe the therapeutic effect of Aldioxa tablets in combination with rabeprazole on peptic ulcer. METHODS One hundred and fourty seven patients with peptic ulcer diagnosed with gastroendoscopy were randomly divided into the study group(n=74) and the control group(n=73). Patients in the study group were treated with Aldioxa tablets orally,0.2 g tid and rabeprazole 20 mg,qd. Patients in the control group were treated with rabeprazole 20 mg,qd. The course of treatment was 4 weeks. In the course of treatment,patients were followed up once a week,and the symptoms of the patients were recorded. After therapy course,the healing rate of ulcerative lesions was examined and evaluated by gastroendoscopy.RESULTS There were no significant difference in clinical symptom improvement and pain relief between two groups(P0.05). The healing rate of ulcerwas 94.6% and the effective rate was 98.6% in the study group,while 81.1% and 89.0% in control group. Their differences were obvious(P0.05). The frequency of adverse events were low in both groups. and patients had well tolerability.CONCLUSION The treatment of Aldioxa tablets in combination with rabeprazole on peptic ulcer can improve the healing rate of ulcerative focus and the effective rate,shorten the healing time of ulcer.

Hideo Honda - One of the best experts on this subject based on the ideXlab platform.

  • Acidified aspirin-induced gastric lesion in rats with hepatic cirrhosis produced by N-nitrosodiethylamine or carbon tetrachloride. Effect of Aldioxa on gastric lesions
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1994
    Co-Authors: Masayuki Uchida, Hiroki Hamura, Satoshi Takagi, Yuji Noguchi, Hiroko Shibata, Hideo Honda
    Abstract:

    Gastric lesion was induced by the oral administration of acidified aspirin in rats with hepatic cirrhosis produced by N-nitrosodiethylamine (NDA) or carbon tetrachloride (CCl4). Gastric lesion by acidified aspirin was aggravated in NDA-induced cirrhosis, but not in CCl4-cirrhotic rats. To clarify this difference in the susceptibility of the gastric mucosa, gastric mucosal blood flow and gastric emptying were measured by the hydrogen gas clearance method and beads method, respectively. Gastric mucosal blood flow was lower and gastric emptying was significantly delayed in NDA-induced cirrhotic rats as compared with the controls, but not in CCl4-induced cirrhotic rats. Gastric mucosal blood flow in NDA-induced cirrhotic rats was significantly decreased by the oral administration of acidified aspirin as compared with the controls. Aldioxa dose-dependently inhibited the gastric lesion formation by acidified aspirin and inhibited the decrease of gastric mucosal blood flow in NDA-induced cirrhotic rats. These results suggest that aggravation of gastric lesion induced by acidified aspirin in NDA-induced cirrhotic rats would be due to the decrease of gastric mucosal blood flow and delay of gastric emptying. In addition, Aldioxa showed a protective effect against gastric lesions induced by acidified aspirin in NDA-induced cirrhotic rats, suggesting that this compound would have an inhibitory effect on gastric lesions that are accompanied by hepatic cirrhosis.

Teita Asano - One of the best experts on this subject based on the ideXlab platform.

  • Aldioxa improves delayed gastric emptying and impaired gastric compliance, pathophysiologic mechanisms of functional dyspepsia
    Scientific Reports, 2015
    Co-Authors: Teita Asano, Shuji Aida, Shintaro Suemasu, Kayoko Tahara, Ken-ichiro Tanaka, Tohru Mizushima
    Abstract:

    Delayed gastric emptying and impaired gastric accommodation (decreased gastric compliance) play important roles in functional dyspepsia (FD). Here we screen for a clinically used drug with an ability to improve delayed gastric emptying in rats. Oral administration of Aldioxa (dihydroxyaluminum allantoinate) partially improved clonidine- or restraint stress-induced delayed gastric emptying. Administration of allantoin, but not aluminium hydroxide, restored the gastric emptying. Both Aldioxa and allantoin inhibited clonidine binding to the α-2 adrenergic receptor, suggesting that antagonistic activity of the allantoin moiety of Aldioxa on this receptor is involved in the restoration of gastric emptying activity. Aldioxa or aluminium hydroxide but not allantoin restored gastric compliance with restraint stress, suggesting that aluminium hydroxide moiety is involved in this restoration. We propose that Aldioxa is a candidate drug for FD, because its safety in humans has already been confirmed and its ameliorating effect on both of delayed gastric emptying and impaired gastric compliance are confirmed here.